Medline shares rise as investors digest recent refinancing and large secondary offering

Medline Inc. (MDLN) is up 6.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a cleanup of near-term balance-sheet and stock-supply overhang concerns following Medline’s recently completed debt refinancing and a large secondary share offering. With the transactions behind the company, investors may be viewing funding risk and uncertainty around insider/PE selling as more “known,” supporting a bounce.

Details:

Medline recently closed an upsized secondary offering of 72,554,594 shares of Class A common stock at $37.00 per share, sold by existing stockholders (not a primary issuance by the company).

In a June 2, 2026 Form 8-K, Medline disclosed that its subsidiaries issued $1.25 billion of 5.000% senior secured notes due 2031 and $750 million of 5.250% senior secured notes due 2033.

The same 8-K described a new $2.75 billion senior secured term loan facility maturing in 2033 and the use of proceeds (along with cash) to repay/refinance prior term loan debt and redeem certain outstanding senior secured notes, plus fees and expenses.

This could be because, after a large secondary and refinancing, some investors step back in once liquidity improves and the immediate “deal overhang” is removed.

Sources:

SEC, Medline Investor Relations, GlobeNewswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDLN Insider Trading Activity

$MDLN insiders have traded $MDLN stock on the open market 41 times in the past 6 months. Of those trades, 5 have been purchases and 36 have been sales.

Here’s a breakdown of recent trading of $MDLN stock by insiders over the last 6 months:

& FRIEDMAN CAPITAL PARTNERS X (PARALLEL), L.P. HELLMAN has made 0 purchases and 11 sales selling 64,087,845 shares for an estimated $2,395,626,592.
8 HOLDINGS MOZART MANAGER L.L.C. BCP has made 0 purchases and 8 sales selling 61,170,810 shares for an estimated $2,345,618,751.
MOZART ML-2 HOLDCO L.P. BX has made 0 purchases and 8 sales selling 61,170,810 shares for an estimated $2,345,618,751.
GROUP INC. CARLYLE has made 0 purchases and 2 sales selling 45,242,173 shares for an estimated $1,625,293,097.
MOZART COINVESTMENT HOLDINGS, L.P. CARLYLE has made 0 purchases and 2 sales selling 45,242,173 shares for an estimated $1,625,293,097.
GROUP CAYMAN INVESTMENT HOLDINGS, L.P. TC sold 26,105,840 shares for an estimated $1,070,339,440
CIRCLE ML HOLDCO GP, LLC CP sold 26,105,840 shares for an estimated $1,070,339,440
PRIVATE LTD GIC has made 1 purchase buying 12,586,206 shares for an estimated $364,999,974 and 1 sale selling 10,204,351 shares for an estimated $289,480,090.
GROUP VII S1, L.L.C. TC sold 19,136,333 shares for an estimated $554,953,657
AGGREGATOR II LP MOZART sold 13,462,600 shares for an estimated $381,911,075
ANDREW J. MILLS purchased 2,586,206 shares for an estimated $74,999,974
CHARLES N. MILLS has made 2 purchases buying 2,579,310 shares for an estimated $74,799,990 and 0 sales.
JESSI L CORCORAN (Principal Accounting Officer) purchased 5,000 shares for an estimated $170,750

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MDLN Hedge Fund Activity

We have seen 260 institutional investors add shares of $MDLN stock to their portfolio, and 61 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CARLYLE GROUP INC. added 215,303,036 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,042,727,512
VANGUARD GROUP INC added 18,887,568 shares (+inf%) to their portfolio in Q4 2025, for an estimated $793,277,856
H&F CORPORATE INVESTORS X, LTD. removed 13,040,572 shares (-13.1%) from their portfolio in Q1 2026, for an estimated $580,305,454
JANUS HENDERSON GROUP PLC added 10,564,621 shares (+inf%) to their portfolio in Q4 2025, for an estimated $443,714,082
BAILLIE GIFFORD & CO added 10,410,371 shares (+inf%) to their portfolio in Q4 2025, for an estimated $437,235,582
FMR LLC added 10,201,987 shares (+38.7%) to their portfolio in Q1 2026, for an estimated $453,988,421
CAPITAL RESEARCH GLOBAL INVESTORS added 8,377,467 shares (+56.7%) to their portfolio in Q1 2026, for an estimated $372,797,281

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDLN Analyst Ratings

Wall Street analysts have issued reports on $MDLN in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Tigress Financial issued a "Buy" rating on 05/13/2026
BTIG issued a "Buy" rating on 01/12/2026
RBC Capital issued a "Outperform" rating on 01/12/2026
Bernstein issued a "Outperform" rating on 01/12/2026
Wolfe Research issued a "Outperform" rating on 01/12/2026
Barclays issued a "Overweight" rating on 01/12/2026
Citigroup issued a "Buy" rating on 01/12/2026

To track analyst ratings and price targets for $MDLN, check out Quiver Quantitative's $MDLN forecast page.

$MDLN Price Targets

Multiple analysts have issued price targets for $MDLN recently. We have seen 24 analysts offer price targets for $MDLN in the last 6 months, with a median target of $49.5.

Here are some recent targets:

Eric Coldwell from Baird set a target price of $45.0 on 06/03/2026
Glen Santangelo from Barclays set a target price of $45.0 on 06/01/2026
Navann Ty from BNP Paribas set a target price of $40.0 on 05/14/2026
Ivan Feinseth from Tigress Financial set a target price of $62.0 on 05/13/2026
David Larsen from BTIG set a target price of $55.0 on 05/07/2026
Lee Hambright from Bernstein set a target price of $54.0 on 05/07/2026
Patrick Donnelly from Citigroup set a target price of $55.0 on 05/07/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.